Edition:
United States

Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

82.50EUR
11:35am EDT
Change (% chg)

€0.92 (+1.13%)
Prev Close
€81.58
Open
€81.88
Day's High
€82.66
Day's Low
€81.85
Volume
416,153
Avg. Vol
624,781
52-wk High
€86.13
52-wk Low
€70.00

Select another date:

Fitch Rates Fresenius Medical Care Bonds 'BBB-'

(The following statement was released by the rating agency) LONDON, May 25 (Fitch) Fitch Ratings has assigned senior unsecured ratings of 'BBB-' to debt instruments issued by the various finance companies of Fresenius Medical Care AG & Co. KG (FMC). The issuing companies are FMC Finance VII S,A., FMC Finance VIII S.A., Fresenius Medical Care US Finance II, Inc. and Fresenius Medical Care US Finance, Inc. The senior unsecured ratings are in line with FMC's Long-Term Issuer Default Rating (IDR) of

BRIEF-Vifor Pharma and Akebia announce license agreement to provide Vadadustat to Fresenius in U.S.

* Vifor Pharma and Akebia announce exclusive license agreement to provide Vadadustat to Fresenius medical care in the U.S. Upon FDA approval

BRIEF-Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

* Akebia and Vifor Pharma announce exclusive license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

UPDATE 1-Fresenius ups guidance on growth at generic drugs unit

* Unit FMC shored up by reimbursement, drug cost control (Adds FMC results, premarket shares)

Dialysis provider FMC posts higher earnings

FRANKFURT Fresenius Medical Care , the German kidney dialysis provider which derives about three quarters of sales from North America, posted a 17 percent gain in quarterly adjusted net income, benefiting from higher reimbursement rates and lower costs of medicines for dialysis patients.

Dialysis provider FMC posts higher earnings

FRANKFURT, May 3 Fresenius Medical Care , the German kidney dialysis provider which derives about three quarters of sales from North America, posted a 17 percent gain in quarterly adjusted net income, benefiting from higher reimbursement rates and lower costs of medicines for dialysis patients.

UPDATE 1-Fresenius aims for double-digit growth through 2020

* FMC sees slowing profit growth in 2017 (Adds details, Fresenius results)

FMC forecasts slowing net income growth for 2017

FRANKFURT, Feb 22 The world's largest kidney dialysis provider Fresenius Medical Care (FMC) said it expected its net income growth to slow to between 7 and 9 percent this year, after a 21 percent jump last year.

UPDATE 1-FMC takes control of Australian outpatient treatment chain

* FMC diversifying into therapeutic areas beyond kidney (Adds strategic rationale, percentage of stake taken, report on price)

FMC buys majority stake in Australian hospital group Cura

FRANKFURT, Feb 3 Germany dialysis specialist Fresenius Medical Care said it was buying a majority stake in Cura Group, a leading operator of high-quality day hospitals in Australia.

Select another date:

More From Around the Web